02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
01:12 , Jun 28, 2019 |  BC Extra  |  Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
00:43 , Jun 22, 2019 |  BC Extra  |  Financial News

WuXi stocks tumble as Rubio continues to press China agenda

WuXi Biologics and WuXi AppTec ended down about 6% in Hong Kong on Friday, losing a combined $765 million in market cap, as Sen. Marco Rubio (R-Fla.) continued to ratchet up pressure on China's life...
23:44 , Jun 19, 2019 |  BC Extra  |  Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations. Bispecific antibody company F-star Biotechnology Ltd . (Cambridge, U.K.) said CFO...
00:12 , Jun 15, 2019 |  BC Extra  |  Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
18:35 , Jun 7, 2019 |  BC Extra  |  Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
23:44 , May 23, 2019 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...